AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03698006
Drug: Ropivacaine 0.2% Injectable Solution
RxNorm normalized name: ROPivacaine 0.2% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infiltration with 25ml of Ropivacaine 0.2% in the posterior knee capsule
Trial: NCT06563297
Drug: Alfentanil
RxNorm normalized name: Alfentanil
DrugBank: Alfentanil (DB00802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We first start with alfentanil 100 ng/ml, and use the up and down method as adjust 25 ng/ml of concentration of alfentanil each time. An SPI higher than 80 and hyperdynamics (the increased HR and MBP up 20% of baseline or HR\>100bpm and ABP\>180/100mmHg) indicates insufficient analgesia, therefore increase it by 25 ng/ml at the next patient; an SPI lower than 80 and stable hemodynamics (the changes of HR and MBP within 20% of baseline or HR\<50bpm and ABP\<90/50mmHg) indicates that analgesia is acceptable, and the next patient will decrease it by 25 ng/ml during skull pin fixation. If the analgesia is inadequate, increase alfentanil concentration will be prescribed. On the other hand, if analgesia is adequate, however hyperdynamics was noted, beta blocker or calcium channel blocker will be prescribed. If hypotension (ABP\<90/50 mmHg) or bradycardia (HR\<50 bpm) occur, we first stop alfentanil infusion and treated with ephedrine or atropine, respectively.
Trial: NCT05020444
Drug: TriPRIL CAR T Cells
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT05020444
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT06149767
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The medication regimen for all enrolled patients is as follows, and the dose can be adjusted during treatment due to adverse reactions and other circumstances:~Adebrelimab : 20 mg/kg, D1, intravenously, 30-60 min, Q3w. Paclitaxel for Injection: 150 mg/m2, D1 Cisplatin: 50 mg/m2, IV, D1, Q3w. Radiotherapy: pelvic dose: 6MV-X, 180cGy/ times 27 times; Brachydose: 192Ir, 700cGy/ time 4 times.~First of all, after 2 cycles of concurrent chemoradiotherapy, the sequential chemotherapy combined with adbalizumab for 2-4 cycles, and the subsequent investigators selected Adbalizumab or other drugs to maintain the treatment according to the patient's situation or the patient's own will until the disease progressed or intolerable toxicity occurred or the subjects voluntarily withdrew from the study.adebrelimab until disease progression or intolerable toxicity or the subject voluntarily withdrew from the study。
Trial: NCT05826119
Drug: magnesium sulfate group
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The magnesium group received a bolus of 20 mg/kg of magnesium sulfate in 100 mL of saline for 15 minutes prior to induction, followed by a continuous infusion of 20 mg/kg/hr until skin closure.
Trial: NCT05341193
Drug: Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip)+gemcitabine (1,000 mg/m2), every 3 weeks for 3 cycles before radiotherapy.~Concurrent therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 2 cycles during radiotherapy.~Adjuvant therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 1 year after radiotherapy.~Radiation:~Intensity-modulated radiotherapy.
Trial: NCT05341193
Drug: Bevacizumab+Toripalimab+gemcitabine, adjuvant with Toripalimab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip)+gemcitabine (1,000 mg/m2), every 3 weeks for 3 cycles before radiotherapy.~Concurrent therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 2 cycles during radiotherapy.~Adjuvant therapy:~Toripalimab (240mg iv drip), every 3 weeks for 1 year after radiotherapy.~Radiation:~Intensity-modulated radiotherapy.
Trial: NCT05960032
Drug: Zavegepant
RxNorm normalized name: Zavegepant
DrugBank: Zavegepant (DB15688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receiving single dose of Zavegepant 10 mg
Trial: NCT06702631
Drug: Nitrous oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After a no-drug control period, subjects will inhale nitrous oxide, administered via a breathing circuit and face mask, until a steady-state target end-tidal expired concentration is reached. During the drug condition, subjects will receive low-dose nitrous oxide (% corresponding to Minimum Alveolar Concentration).
Trial: NCT06440304
Drug: Fosfomycin
RxNorm normalized name: FOSFOMYCIN
DrugBank: Fosfomycin (DB00828)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be randomly divided according to a predetermined randomization table Upon arrival of a positive microbiological finding on A. baumannii, patient will be randomised to one of groups (Colistin with Unasyn OR Colistin with Xerava OR Colistin with Fosfomycin
Trial: NCT06440304
Drug: Eravacycline
RxNorm normalized name: Eravacycline
DrugBank: Eravacycline (DB12329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomly divided according to a predetermined randomization table Upon arrival of a positive microbiological finding on A. baumannii, patient will be randomised to one of groups (Colistin with Unasyn OR Colistin with Xerava OR Colistin with Fosfomycin
Trial: NCT06440304
Drug: ampicillin/sulbactam
RxNorm normalized name: AMPICILLIN/SULBACTAM
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be randomly divided according to a predetermined randomization table Upon arrival of a positive microbiological finding on A. baumannii, patient will be randomised to one of groups (Colistin with Unasyn OR Colistin with Xerava OR Colistin with Fosfomycin
Trial: NCT05459701
Drug: Dapagliflozin 10mg Tab
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin 10 mg once daily for 24 weeks.
Trial: NCT00001991
Drug: Atovaquone
RxNorm normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00015691
Drug: Metformin hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00015691
Drug: Rosiglitazone maleate
RxNorm normalized name: Rosiglitazone Maleate
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04981704
Drug: Poziotinib
RxNorm normalized name: Poziotinib
DrugBank: Poziotinib (DB12114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poziotinib Tablets
Trial: NCT04981704
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole Oral solution
Trial: NCT04981704
Drug: Paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paroxetine Tablets
Trial: NCT01039363
Drug: Salvage reinduction chemotherapy including Gemtuzumab ozogamicin, Idarubicin and Cytarabine and Vorinostat
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Salvage reinduction therapy:~Vorinostat 200mg BID po (D1-14) Gemtuzumab ozogamicin 3 mg/m2 once (D1) Idarubicin 12mg/m2 for 2 days (D2-3) Cytarabine 500mg/m2 bid IV for 5 days (D2-6)~Maintenance:~Once achieved CR, then Vorinostat 200mg BID po for 2 weeks, then 1 week's rest (1 cycle) for 11 cycles~* Vorinostat should be stopped at least 2 weeks ahead of starting of consolidation therapy.~* Gemtuzumab will be omitted in a consolidation schedule.~* Allogeneic hematopoietic stem cell transplantation (HSCT) can be performed if HLA-matched sibling or unrelated donor is available. Vorinostat will be stopped 2 weeks prior to starting of conditioning regimen for allogeneic HSCT.
Trial: NCT05387603
Drug: 177Lu-DOTATOC
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational medicinal product (IMP) is 177Lu-DOTATOC which is registered as an orphan drug by the EMA ( European Medicines Agency) for the treatment of GEP-NEN (gastro-entero-pancreatic neuroendocrine tumor).~The IMP will be administered to participants both in the control arm and the experimental arms, but with different intervals, but the same activity; 7.5 Gbq per dosing.
Trial: NCT05775874
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab:200mg Q3W
Trial: NCT06412861
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg ketamine + 1 mg/kg propofol, Ramsey Sedation Score \> 4 will be targeted. For this, if necessary, additional iv 0.5 mg/kg propofol will be administered.
Trial: NCT06562647
Drug: SY001
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PBMC-derived anti-mesothelin Cheimeric Antigen Receptor macrophages
Trial: NCT05163041
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab will be given as a 240mg dose every 2 weeks administered as per local labelling as a 30 minute IV infusion
Trial: NCT06261203
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To investigate the efficacy of low dose aspirin for prevention of early pregnancy loss in women at high risk of preeclampsia.
Trial: NCT05027100
Drug: Anlotinib Tislelizumab Irinotecan
RxNorm normalized name: Tislelizumab
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Anlotinib 10mg QD 2W stop 1W Tislelizumab injection200mg Q3W Irinotecan (2 cycles) 100mg/m2,d1,d8,Q3W
Trial: NCT05959889
Drug: Montelukast
RxNorm normalized name: Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive motelukast 10 mg for 4 cycles of AC.
Trial: NCT05297968
Drug: Oseltamivir Phosphate For Oral Suspension/Tamiflu
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the subjects randomly received single oral administration of Oseltamivir Phosphate For Oral Suspension/Tamiflu 75mg (6mg/ml,12.5ml)
Trial: NCT05297968
Drug: Oseltamivir Phosphate For Oral Suspension
RxNorm normalized name: Oseltamivir Phosphate for Oral Suspension
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the subjects randomly received single oral administration of Oseltamivir Phosphate For Oral Suspension 75mg (6mg/ml,12.5ml)
Trial: NCT06541327
Drug: Chimeric Antigen Receptor
RxNorm normalized name: Chimeric antigen receptor
DrugBank: B7-H3-specific chimeric antigen receptor T cells (DB18567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAR-T
Trial: NCT05180422
Drug: AMG 510
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous once daily (QD) oral dosing (Days 1-21 each cycle) with or without food.
Trial: NCT05180422
Drug: MVASI
RxNorm normalized name: Mvasi
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous (i.v.) infusion every 21 days (i.e. Day 1 of each 21-day cycle).
Trial: NCT01675986
Drug: hydroxyzine
RxNorm normalized name: Hydroxyzine
DrugBank: Hydroxyzine (DB00557)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg
Trial: NCT01675986
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 150 mg
Trial: NCT06759363
Drug: Sodium-Butyrate
RxNorm normalized name: butyrate
DrugBank: Butyric Acid (DB03568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/day of sodium-butyrate
Trial: NCT04456439
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive diphenhydramine, 0.5-1 mg/kg, up to 50 mg IV, at least 30 minutes prior to the infusion of remestemcel-L.
Trial: NCT06467513
Drug: Esketamine hydrochloride injection
RxNorm normalized name: esketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The low dose esketamine hydrochloride group was given 0.2mg/kg at induction of anesthesia, the high dose esketamine hydrochloride group was given 0.4mg/kg at induction of anesthesia, and the blank control group was not given Esketamine hydrochloride injection at induction of anesthesia.
Trial: NCT04971005
Drug: Autologous Hematopoietic Stem Cell Transplantation
RxNorm normalized name: human cord blood hematopoietic progenitor cell
DrugBank: Human cord blood hematopoietic progenitor cell (DB11054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous Hematopoietic Stem Cell Transplantation
Trial: NCT04971005
Drug: Ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 600 mg every 6 months continuously
Trial: NCT04971005
Drug: Alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 12 mg/day for 5 consecutive days and again after 365 days for 3 days
Trial: NCT04743557
Drug: DYN101
RxNorm normalized name: DYN101
DrugBank: DYN-101 (DB17921)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DYN101, is a constrained ethyl gapmer ASO directed against human DNM2 pre-mRNA
Trial: NCT05429294
Drug: Pyrotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with HER2-positive advanced/metastatic breast cancer are treated with pyrotinib combined with trastuzumab and albumin paclitaxel in the first-line setting.
Trial: NCT05872087
Drug: Nebulised Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: premedication by nebulised midazolam 0.3mg/kg in children undergoing lower abdominal surgeries
Trial: NCT00932763
Drug: Amlodipine besylate
RxNorm normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg tablets (Torrent Pharmaceuticals, India)
Trial: NCT00932763
Drug: Norvasc
RxNorm normalized name: Norvasc
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg dose (Pfizer, USA)
Trial: NCT04291937
Drug: Lurbinectedin
RxNorm normalized name: LURBINECTEDIN
DrugBank: Lurbinectedin (DB12674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Powder for concentrate for solution for infusion in 4 mg vials
Trial: NCT06622239
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naltrexone 50mg for 6 weeks
Trial: NCT05497063
Drug: Sulfadoxine/Pyrimethamine dispersible tablets, 250 mg sulfadoxine / 12.5 mg pyrimethamine & 500 mg sulfadoxine / 25 mg pyrimethamine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two tablets of 250 mg sulfadoxine / 12.5 mg pyrimethamine or 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
Trial: NCT05881915
Drug: Phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: phenylephrine infusion at rate of 0.4 mcg/Kg/min. (10 mg /1 mL) will be diluted to reach a final concentration of 10 mcg/mL
Trial: NCT06341842
Drug: Dapagliflozin 10mg Tab
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapaglifloziin 10 mg 1 tab daily
Trial: NCT04739358
Drug: Tepotinib
RxNorm normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will receive tepotinib daily in cycles of 21-day duration. Subjects in the Combination Therapy arm will continue to receive their last tolerable dose of tyrosine kinase inhibitor (TKI) together with tepotinib.
Trial: NCT06589635
Drug: ADC-189 and Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part 1:~Day 1, fasting condition, 45 mg ADC189, administered orally~Part 2:~Day 22, 200 mg itraconazole bid, taken orally after meals. Day 23-Day 25, 200 mg itraconazole was taken orally after meals. Day 26, 45 mg ADC-189 and 200 mg itraconazole was taken orally after meals. Day 27-Day 39, 200 mg itraconazole was taken orally after meals.
Trial: NCT05755087
Drug: Tegavivint
RxNorm normalized name: Tegavivint
DrugBank: Tegavivint (DB17109)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05830799
Drug: Drug Drug Interaction
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention phase consists of 3 periods: in period 1, the pharmacokinetics (PK) of all substrates will be evaluated in the absence of C21, in period 2, a potential inhibitory effect of C21 on the substrates be evaluated, and in period 3, the net effect of potential C21-mediated induction and inhibition on the substrates will be evaluated
Trial: NCT05364177
Drug: 68Ga-Pentixather
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After intravenous injection of 68Ga-pentixather, PET/CT scan will be performed.
Trial: NCT05364177
Drug: 68Ga-Pentixafor
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After intravenous injection of 68Ga-pentixafor, PET/CT scan will be performed.
Trial: NCT05229380
Drug: Saccharin test
RxNorm normalized name: Saccharin
DrugBank: Saccharin (DB12418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharin is a nonnutritive sweetener. It has property of being inert to respiratory epithelium that is it does not hamper physiological mucus clearance of sino-nasal mucosa. Methylene blue is a chemical compound. It can be used to check patency of (ET). The dye, because of its liquid form, gravitates through the ET to the nasopharynx.
Trial: NCT04703335
Drug: Antimicrobial efficacy of gel ZHCK4 as a patient preoperative skin preparation
RxNorm normalized name: povidone-iodine
DrugBank: Fica (DB03384)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Evaluate the antimicrobial efficacy of two concentrations of one patient preoperative skin preparation product compared to a positive control (2.0% chlorhexidine gluconate) and negative control (physiological saline 0.9% solution). Following a 14-day restriction period, subjects will be sampled for baseline, 10-minutes, 6-hours, and 24-hours microbial reduction evaluations post-product application. Subjects will not be sequestered for the 6-hour or 24-hour evaluations. Test day baseline criteria will be set at: abdomen: ≥ 3.0 log10 CFU/cm2, and inguen: ≥ 5.0 log10 CFU/cm2.
Trial: NCT05854082
Drug: Lidocaine 2% Polyampoule
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three intervention conditions in a repeated measures design - lidocaine; no perturbation, candy (lollipop)
Trial: NCT05544916
Drug: XC221
RxNorm normalized name: XC221
DrugBank: XC221 (DB16503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day, for 5 days
Trial: NCT05767905
Drug: PF-06821497 Treatment A
RxNorm normalized name: PF-06821497
DrugBank: PF-06821497 (DB14799)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of PF-06821497 administered under fasting conditions.
Trial: NCT05767905
Drug: PF-06821497 Treatment B
RxNorm normalized name: PF-06821497
DrugBank: PF-06821497 (DB14799)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of PF-06821497 administered under fasting conditions.
Trial: NCT05767905
Drug: PF-06821497 Treatment C
RxNorm normalized name: PF-06821497
DrugBank: PF-06821497 (DB14799)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of PF-06821497 administered under fasting conditions.
Trial: NCT05767905
Drug: PF-06821497 Treatment D
RxNorm normalized name: PF-06821497
DrugBank: PF-06821497 (DB14799)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of PF-06821497 administered under fasting conditions.
Trial: NCT05767905
Drug: PF-06821497 Treatment E
RxNorm normalized name: PF-06821497
DrugBank: PF-06821497 (DB14799)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of PF-06821497 administered after low fat meal
Trial: NCT05767905
Drug: PF-06821497 Treatment F
RxNorm normalized name: F
DrugBank: PF-06821497 (DB14799)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of PF-06821497 administered after high fat meal.
Trial: NCT05173298
Drug: atezolizumab plus bevacizumab
RxNorm normalized name: Atezolizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1200 mg of atezolizumab plus 15 mg/kg of body weight of bevacizumab intravenously every 3 weeks